Are you Dr. Ingenito?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 40 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1023 Quincy Ave
Scranton, PA 18510Phone+1 310-279-7749- Is this information wrong?
Summary
- Dr. Gary Ingenito, MD is a neurologist in Scranton, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
- University of Miami/Jackson Health SystemResidency, Neurology, 1986 - 1989
- University of Miami/Jackson Health SystemResidency, Neurological Surgery, 1984 - 1986
- University of Miami/Jackson Health SystemInternship, Transitional Year, 1983 - 1984
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1983
Certifications & Licensure
- PA State Medical License 1991 - 2024
Clinical Trials
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Start of enrollment: 2018 Apr 18
Publications & Presentations
PubMed
- 5 citationsIn Vivo Detection of CPP-115 Target Engagement in Human BrainAndrew P. Prescot, Steven R. Miller, Gary Ingenito, Rebekah S. Huber, Douglas G. Kondo, Perry F. Renshaw> ;Neuropsychopharmacology. 2018 Feb 1
- 227 citationsEfficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.Siegfried Kasper, Mark N. Lerman, Robert D. McQuade, A. Saha, William H. Carson, Mirza Ali, Donald G. Archibald, Gary G. Ingenito, Ronald N. Marcus, Teresa A. Pigott> ;The International Journal of Neuropsychopharmacology. 2003 Dec 1
- 336 citationsA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.Paul E. Keck, Ronald N. Marcus, Stavros Tourkodimitris, Mirza Ali, Amy Liebeskind, A. Saha, Gary G. Ingenito> ;The American Journal of Psychiatry. 2003 Sep 1
- Join now to see all
Press Mentions
- Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to Be Presented at the Upcoming American Academy of Neurology 2023 Annual MeetingApril 20th, 2023
- Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic EpilepsiesMarch 8th, 2023
- Catalyst Pharmaceuticals’ Firdapse® (Amifampridine Phosphate) Receives Marketing Approval in Canada for Patients with LEMSAugust 6th, 2020
- Join now to see all